News | June 23, 2021
Shilpa Medicare launches dissolving oral thin films of Paracetamol
Shilpa's Paracetamol oral thin films are patent protected and are first of this kind in the world
Shilpa's Paracetamol oral thin films are patent protected and are first of this kind in the world
The end user can validate the authenticity of the product by scanning the digital code with the help of a smartphone letting the end user know it is safe to use
This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
The study was conducted in patients with mild to moderate COVID-19
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
Subscribe To Our Newsletter & Stay Updated
